Biorelate
AI biomedicine analysis and trend platform
- 21-100 employees
- Healthcare
- B2B
- Artificial Intelligence
- Analytics
- SaaS
- MedTech
- Chorlton-on-Medlock, Manchester, UK
Jump to section
Company mission
To curate knowledge to advance the world's most promising biomedical innovations.
Our take
With an increasing number of data analysis and compilation tools and methods available across the sciences, a tangible channel for actionable insights based upon accurate analysis is vital. With so many discoveries, it’s easy for information to outpace digestion. Biorelate’s Galactic AI cloud computing software is a solution to this, providing a comprehensive and ever-refreshing catalogue of biomedical research for scientists.
The Galactic AI platform provides actionable and relevant data by “auto-ingesting” patents, clinical trials, journal articles, and more. It works with a range of computer technologies including TensorFlow and Google Cloud to remain scaleable and accessible, all with actions in place to keep data secure and its throughline transparent.
BioRelate was founded in 2014 and continues to secure funding into the present. Its funding is being invested toward boosting its product capabilities, sales, and marketing. BioRelate is also planning an expansion into the US.
Freddie
Company Specialist at Welcome to the Jungle
Benefits
- Genuine Flexibility: We are a fully remote business with colleagues across the globe, manage your schedule, save time and money on commuting, and do your best work from the comfort of your home.
- Supportive Environment: We value meaningful collaboration and prioritise the well-being of our team.
- Cutting-Edge Technology: You'll work with the latest software tools and technologies.
Funding (last 2 of 3 rounds)
Nov 2022
$8.8m
SERIES A
Sep 2018
$1m
SEED
Total funding: $9.9m
Leadership
Daniel Jamieson
(Founder & CEO)Former member of the Early Career Advisory Panel for the Biochemical Society, PhD student at the University of Manchester, and was a Bioinformatician at both Pfizer and Merck.